A Landscape of Pharmacogenomic Interactions in Cancer

Francesco Iorio(European Bioinformatics Institute), Theo Knijnenburg(The Netherlands Cancer Institute), Daniël J. Vis(The Netherlands Cancer Institute), Graham R. Bignell(Wellcome Sanger Institute), Michael P. Menden(European Bioinformatics Institute), Michaël Schubert(European Bioinformatics Institute), Nanne Aben(The Netherlands Cancer Institute), Emanuel Gonçalves(European Bioinformatics Institute), Syd Barthorpe(Wellcome Sanger Institute), Howard Lightfoot(Wellcome Sanger Institute), Thomas Cokelaer(European Bioinformatics Institute), Patricia Greninger(Harvard University), Ewald van Dyk(The Netherlands Cancer Institute), Han Chang(Bristol-Myers Squibb (United States)), Heshani de Silva(Bristol-Myers Squibb (United States)), Holger Heyn(Institut d'Investigació Biomédica de Bellvitge), Xianming Deng(Harvard University), Regina K. Egan(Harvard University), Qingsong Liu(Harvard University), Tatiana Mironenko(Wellcome Sanger Institute), Xeni Mitropoulos(Harvard University), Laura Richardson(Wellcome Sanger Institute), Jinhua Wang(Harvard University), Tinghu Zhang(Harvard University), Sebastián Morán(Institut d'Investigació Biomédica de Bellvitge), Sergi Sayols(Institut d'Investigació Biomédica de Bellvitge), Maryam Soleimani(Wellcome Sanger Institute), David Tamborero(Universitat Pompeu Fabra), Núria López-Bigas(Institució Catalana de Recerca i Estudis Avançats), Petra Ross‐Macdonald(Bristol-Myers Squibb (United States)), Manel Esteller(Institució Catalana de Recerca i Estudis Avançats), Nathanael S. Gray(Harvard University), Daniel A. Haber(Howard Hughes Medical Institute), Michael R. Stratton(Wellcome Sanger Institute), Cyril H. Benes(Harvard University), Lodewyk F.A. Wessels(The Netherlands Cancer Institute), Julio Sáez-Rodríguez(European Bioinformatics Institute), Ultan McDermott(Wellcome Sanger Institute), Mathew J. Garnett(Wellcome Sanger Institute)
Cited by 2,246Open Access
Full Text

Abstract

Systematic studies of cancer genomes have provided unprecedented insights into the molecular nature of cancer. Using this information to guide the development and application of therapies in the clinic is challenging. Here, we report how cancer-driven alterations identified in 11,289 tumors from 29 tissues (integrating somatic mutations, copy number alterations, DNA methylation, and gene expression) can be mapped onto 1,001 molecularly annotated human cancer cell lines and correlated with sensitivity to 265 drugs. We find that cell lines faithfully recapitulate oncogenic alterations identified in tumors, find that many of these associate with drug sensitivity/resistance, and highlight the importance of tissue lineage in mediating drug response. Logic-based modeling uncovers combinations of alterations that sensitize to drugs, while machine learning demonstrates the relative importance of different data types in predicting drug response. Our analysis and datasets are rich resources to link genotypes with cellular phenotypes and to identify therapeutic options for selected cancer sub-populations.


Related Papers

No related papers found

Powered by citation graph analysis